Capabilities

Licensing and research collaboration agreement with Regenerex

Novartis

Our client Novartis entered into an exclusive global licensing and research collaboration agreement with biopharmaceutical company Regenerex LLC for the use of the company’s innovative Facilitating Cell Therapy (FCRx) platform.

FCRx will broaden the current Novartis cell therapy portfolio, which includes two novel cell therapy platforms initially being investigated in hematological malignancies.

 

Email Disclaimer